FAQ/Help |
Calendar |
Search |
Today's Posts |
07-24-2014, 10:29 AM | #1 | ||
|
|||
Member
|
AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine
VIENNA, July 24, 2014 /PRNewswire via COMTEX/ -- VIENNA, July 24, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC (Coordinated Universal Time) Where: New York Marriott East Side Hotel 525 Lexington Ave, New York Room Morgan A Live webcast link: http://totalwebcasting.com/view/?id=affiris Who: Walter Schmidt, PhD: CEO & Co-founder, AFFiRiS AG Todd Sherer, PhD: CEO, The Michael J. Fox Foundation Prof. Achim Schneeberger, MD: CMO, AFFiRiS AG If you are unable to attend the press conference, please visit the aforementioned web link for a live webcast. An embedded message board will allow you to participate in the Q&A. A recording of the conference will be made available immediately after the press conference at http://totalwebcasting.com/view/?id=affiris About AFFiRiS AG Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria ( http://www.affiris.com ). http://www.marketwatch.com/story/med...ine-2014-07-24 |
||
Reply With Quote |
07-24-2014, 01:59 PM | #2 | ||
|
|||
Member
|
Badboy, thanks for posting the link. I'll be at the presentation and I'm very interested in seeing the early results. The vaccine still has a long way to go, but it could be a breakthrough development if it works.
|
||
Reply With Quote |
"Thanks for this!" says: | badboy99 (07-24-2014) |
07-24-2014, 03:45 PM | #3 | ||
|
|||
Member
|
Please give us a full report on anything you hear that's not broadcast. Thank you.
|
||
Reply With Quote |
07-31-2014, 11:01 AM | #4 | ||
|
|||
Member
|
Quote:
With regard to preliminary efficacy, the two test groups remained stable throughout the year while the placebo group had deterioration. Even with the small sample sizes the results were significant. Interesting, not all of the test group subjects actually reacted to the vaccine with a buildup of a-syn antibodies. Only about half of the test group had antibodies in serum samples. When analyzed for only those that had the antibodies, the results much more evident. The company intends to begin the next study immediately. They are considering adding on locations in the US (they are located in Austria). Press Release: http://www.affiris.com/html/en/press...meldungen.html |
||
Reply With Quote |
"Thanks for this!" says: | lab rat (07-31-2014), soccertese (07-31-2014) |
07-31-2014, 11:19 AM | #5 | ||
|
|||
Magnate
|
crossing my fingers. pretty small group.
|
||
Reply With Quote |
07-31-2014, 11:25 AM | #6 | ||
|
|||
Member
|
I have high hopes. It's past 11am Eastern time??
|
||
Reply With Quote |
07-31-2014, 11:27 AM | #7 | ||
|
|||
Member
|
Check out the slides once they are live.
|
||
Reply With Quote |
07-31-2014, 11:28 AM | #8 | ||
|
|||
Member
|
It was, but phase I usually is. Not sure you could have had any better results other than the possibility that only some PwP will react to the vaccine. It will be interesting to see how they explain that, and if they can reconfigure for others.
|
||
Reply With Quote |
07-31-2014, 11:29 AM | #9 | ||
|
|||
Member
|
|
||
Reply With Quote |
"Thanks for this!" says: | soccertese (07-31-2014) |
07-31-2014, 11:35 AM | #10 | ||
|
|||
Magnate
|
i assume MJFF will do a webinar to put things in perspective?
|
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Low accuracy of clinical diagnosis for early Parkinson’s disease | Parkinson's Disease | |||
New NIH Clinical Study Looking for Volunteers with Early Onset Parkinson’s | Parkinson's Disease | |||
MJFF Funds AFFiRiS AG to Develop Parkinson's Vaccine | Parkinson's Disease | |||
May2009: Ceregene Presents Additional Clinical Data Phase 2 Trial of CERE-120 for PD | Parkinson's Disease | |||
Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease | Parkinson's Disease Clinical Trials |